Quest Diagnostics Inc vs iShares Semiconductor ETF — how do they compare? Quest Diagnostics Inc trades at $204.5 (market cap $22.80B), while iShares Semiconductor ETF trades at $550.62. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals.
| DGX | SOXX | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.02 | $655.01 |
52-Week Low | $166.42 | $236.93 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SOXX trades at $553.1, down 4.82% over 24 hours amid a broader semiconductor selloff. Technical indicators show a bearish trend with support at $530 and resistance at $557. The ETF has delivered exceptional YTD performance with 93.3% gains through July 6, 2026, driven by AI demand, though recent volatility has erased some gains. A dividend of $0.28 is scheduled for June 2026.
Outlook remains mixed with strong AI-driven growth potential offset by sector volatility and Michael Burry's bearish bet. Key risks include semiconductor cyclicality and geopolitical tensions. The ETF offers diversified exposure to leading chip companies but faces near-term pressure from the recent correction.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →